Showing results (131-140 of 147) with videos related to
Sort By:
Pageof 15
Annals of Hematology|February 27, 2016
Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH)Iris Appelmann, Stephan Kreher, Stefani Parmentier, et al.Investigational New Drugs|September 18, 2015
Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumorsSandrine J Faivre, Anthony J Olszanski, Karin Weigang-Köhler, et al.Transplantation|October 25, 2006
Association of human leukocyte antigen haplotypes with posttransplant lymphoproliferative disease after solid organ transplantationMarion Subklewe, René Marquis, Sylvain Choquet, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2020
TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO-001 TrialMarianne Sinn, Bruno V Sinn, Denise Treue, et al.The Lancet. Oncology|December 17, 2011
Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trialRalf Trappe, Stephan Oertel, Veronique Leblond, et al.Oncology Research and Treatment|May 26, 2025
CONKO-011/AIO-SUP-0115/ass.: Rivaroxaban Compared to Low Molecular Weight Heparin in Cancer Patients with Acute Venous ThromboembolismMarianne Sinn, Anja Lohneis, Omar Mohamed, et al.Thrombosis and Haemostasis|September 22, 2017
Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI TrialAlok A Khorana, Saroj Vadhan-Raj, Nicole M Kuderer, et al.JAMA|January 18, 2007
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trialHelmut Oettle, Stefan Post, Peter Neuhaus, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2017
CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III TrialMarianne Sinn, Marcus Bahra, Torsten Liersch, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2016
Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II TrialRalf U Trappe, Daan Dierickx, Heiner Zimmermann, et al.Pageof 15